FRAGILE X SYNDROME (FXS)
Fully enrolled and not recruiting for Phase 2 Study
The Phase 2 study evaluating the safety, efficacy, tolerability, pharmacokinetics, and pharmacodynamics of SPG601 in adult men with Fragile X syndrome is now completed.
The FDA has approved the U.S. IND (IND 169282) and granted both Orphan Drug and Fast Track designations to SPG601 for the treatment of FXS.
Clinical Trial Sites are Fully Enrolled in the U.S.:
NCT06413537
Status: Completed
Location
Cincinnati, Ohio at Cincinnati Children’s Hospital Medical Center
Contact: Dr. Craig Erickson craig@spinogenix.com
For additional information, visit ClinicalTrials.gov
